Shionogi & Co., Ltd., an R&D pharmaceutical company, has announced that S-649266, an investigational parenteral siderophore cephalosporin, exhibits marked potency against gram-negative bacteria, including multidrug-resistant, or MDR, pathogens, in ... Individual.com, 1 week ago
Shionogi announces encouraging data from bacterial infection studies - Individual.com, 1 month ago
MedImmune, a biologics R&D arm of AstraZeneca, and Shionogi & Co., Ltd., a drug discovery-based pharmaceutical company, have entered into a license agreement under which MedImmune will in-license Shionogi's novel preclinical biologic program for the ...Individual.com, 1 week ago MedImmune in-licenses Shionogi biologic program in ACS Drug Discovery News, 1 week ago MedImmune and Shionogi sign license agreement for Shionogi's preclinical biologics in acute coronary syndrome Pharma Letter, 1 week ago AZ licenses ACS programme from old partner Shionogi Big News Network, 1 week ago
OSAKA Tax authorities have notified drug maker Shionogi & Co. that it failed to report ¥40.5 billion in taxable income over a three-year period to March 2013. Given the Osaka Regional Taxation Bureau's decision, the firm said Friday it plans to ...Japan Times, 1 month ago Shionogi hit with ¥40 billion in back taxes over deal previously thought exempt Japan Times, 1 month ago
Shionogi & Co., Ltd., an R&D pharmaceutical company, has announced that C & O Pharmaceutical Technology Holdings Limited has launched Rabeprazole Sodium for Injection in China. Proton-pump inhibitors (PPIs) inhibit gastric acid secretion by blocking ...Individual.com, 2 weeks ago SHIONOGI : C&O Launches the First Rabeprazole Sodium for Injection (???®) in China 4 Traders, 3 weeks ago C&O Launches the First Rabeprazole Sodium for Injection (???®) in China Noodls, 3 weeks ago Pragma Pharmaceuticals Announces Re-Launch of Moxatag® Pharmacy Times, 1 month ago
Allergan Japan KK, a health care company, and Shionogi & Co., Ltd. have entered into joint sales agreement to distribute GlashVista cutaneous solution 0.03% 5ml for eyelash hypotrichosis treatment in Japan. Under this agreement, Allergan Japan will ...Individual.com, 1 month ago Evonik to expand specialty silica capacities in Japan Business Standard India, 1 month ago Evonik Expands in Japan Adhesives & Sealants Industry, 1 month ago Evonik's Specialty Silica Capacity to Expand in Japan, PPG Starts Marketing Campaign, Scientists Develop PLLA Nanosheets Special Chem 4 Coatings, 1 month ago
Jiji Press OSAKA (Jiji Press) — Tax authorities have notified Shionogi & Co. that the major drug maker failed to report ¥40.5 billion in taxable income over three years to March 2013, the company said Friday. Following the notification by the ...The Japan News, 1 month ago
BuzzeoPDMA reported that Shionogi Inc. has selected BuzzeoPDMA's sample management services. "Working with one vendor who can provide a number of different Sample Accountability and field-based inventory services has been a real benefit, and ...4 Traders, 1 month ago Shionogi Utilizes BuzzeoPDMA's Services Individual.com, 1 month ago Shionogi & Co., Ltd. Enlists A Company To Support Their Sample Management Compliance Programs BioSpace, 1 month ago Shionogi Inc. Enlists BuzzeoPDMA, a Cegedim Company to Support their Sample Management Compliance Programs RCL Advisors, 1 month ago
News Editor Citing an insufficient Rapiacta royalty stream from partner Shionogi & Co. to pay accrued interest in arrears on the non-recourse PharRMA Notes by the September 1, 2014 payment date, a BioCryst Pharmaceuticals (BCRX -0.8%) subsidiary ...Seeking Alpha, 1 month ago BIOCRYST PHARMACEUTICALS INC FILES (8-K) Disclosing Regulation FD Disclosure Crawford Financial Planning, 1 month ago
Shionogi Inc. Announces Four Abstracts To Be Presented At The 25th Annual Meeting Of The North American Menopause Society (NAMS) In Washington, DC
FLORHAM PARK, N.J. , Oct. 1, 2014 /PRNewswire/ -- Shionogi Inc., a global leader dedicated to women's health, will unveil four abstracts containing new analyses and safety and efficacy data from clinical trials of ospemifene (available in the U.S.Franklin Credit Management Corporation, 2 weeks ago Shionogi, Inc. Announces Four Abstracts To Be Presented At The In Washington, DC BioSpace, 2 weeks ago
More from: , TickerTech.com...and 5 other sources
SHIONOGI : Presents Pre-Clinical and Phase I Results For S-649266, A Novel Siderophore Cephalosporine Antibiotic With Potential To Treat...
Shionogi Presents Pre-Clinical and Phase I Results For S-649266, A Novel Siderophore Cephalosporine Antibiotic With Potential To Treat Multidrug-Resistant Gram-Negative Pathogens By a News Reporter-Staff News Editor at Biotech Week -- -Findings ...4 Traders, 1 month ago Shionogi Presents Pre-Clinical and Phase I Results For S-649266, A Novel Siderophore Cephalosporine Antibiotic With Potential To Treat Multidrug-Resistant Gram-Negative Pathogens Minyanville, 1 month ago Shionogi & Co., Ltd. Presents Pre-Clinical And Phase I Results For S-649266, A Novel Siderophore Cephalosporine Antibiotic With Potential To Treat Multidrug-Resistant Gram-Negative Pathogens BioSpace, 1 month ago Novel Antibiotic Shows Potential for Broad Range of Infections Biotech Daily, 4 weeks ago
on your WebpageAdd Widget >Get your members hooked!